TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Neurotech International ( (AU:NTI) ) just unveiled an update.
Neurotech International has initiated an Authorised Prescriber program for its lead therapy, NTI164, in Australia, aimed at expanding access and collecting real-world data to support regulatory submissions and market positioning. Additionally, the company received a Rare Pediatric Disease Designation from the US FDA for NTI164 in treating Rett Syndrome, enhancing its strategic position and regulatory support, while progressing with long-term safety studies and planning further clinical trials.
More about Neurotech International
Neurotech International Ltd is a clinical-stage biopharmaceutical company focused on developing treatments for pediatric neurological disorders. The company is involved in advancing therapies such as NTI164, which targets conditions like Rett Syndrome and autism spectrum disorders, leveraging its proprietary Cannabis sativa strain.
Average Trading Volume: 1,578,474
Technical Sentiment Signal: Sell
Current Market Cap: A$19.42M
See more insights into NTI stock on TipRanks’ Stock Analysis page.